|
gptkbp:instanceOf
|
biotechnology company
|
|
gptkbp:acquisition
|
gptkb:Aquila_Biolabs
MediGene's_acquisition_of_the_rights_to_the_T-cell_therapy_platform
|
|
gptkbp:CEO
|
gptkb:Peter_Llewellyn-Davies
|
|
gptkbp:clinicalTrials
|
solid tumors
hematological malignancies
Phase 1 trials for T-cell therapy
Phase 2 trials for EndoTAG-1
Phase 3 trials planned
|
|
gptkbp:collaborations
|
gptkb:Charité_–_Universitätsmedizin_Berlin
gptkb:University_of_Munich
gptkb:University_of_Heidelberg
|
|
gptkbp:conference
|
gptkb:American_Association_for_Cancer_Research
gptkb:European_Society_for_Medical_Oncology
gptkb:BIO_International_Convention
|
|
gptkbp:employeeCount
|
over 100
|
|
gptkbp:focus
|
oncology
immunotherapy
|
|
gptkbp:founded
|
1994
|
|
gptkbp:headquarters
|
gptkb:Martinsried,_Germany
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
MediGene
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:investmentFocus
|
Venture capital funding
|
|
gptkbp:location
|
gptkb:Germany
|
|
gptkbp:market
|
approximately €200 million
|
|
gptkbp:partnerships
|
gptkb:AstraZeneca
gptkb:Boehringer_Ingelheim
gptkb:Pfizer
Sanofi
Merck KGaA
|
|
gptkbp:patentCitation
|
patents in cancer treatment
patents in immunotherapy
|
|
gptkbp:products
|
EndoTAG-1
Medi-573
Tcell-therapy
|
|
gptkbp:regulatoryCompliance
|
gptkb:European_Medicines_Agency
FDA_approval_for_clinical_trials
|
|
gptkbp:research
|
public and private funding sources
|
|
gptkbp:research_areas
|
metabolic disorders
autoimmune diseases
infectious diseases
|
|
gptkbp:researchFocus
|
antibody-drug conjugates
T-cell engagers
|
|
gptkbp:researchInterest
|
gptkb:Max_Planck_Institute
gptkb:German_Cancer_Research_Center
gptkb:Fraunhofer_Institute
|
|
gptkbp:strategicGoals
|
enhance shareholder value
expand global presence
develop innovative therapies
|
|
gptkbp:subsidiary
|
gptkb:MediGene_AG
|
|
gptkbp:technology
|
biologics
small molecules
cell-based therapies
|
|
gptkbp:tradedOn
|
gptkb:Frankfurt_Stock_Exchange
|
|
gptkbp:website
|
www.medigene.com
|